United States

People: Evoke Pharma Inc (EVOK.OQ)

EVOK.OQ on NASDAQ Stock Exchange Capital Market

3:59pm EST
Change (% chg)

$0.10 (+3.40%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Carlson, Marilyn 

Dr. Marilyn R. Carlson D.M.D., M.D., RAC., is Chief Medical Officer since December 2013. Dr. Carlson has worked closely with Evoke since the company was founded in 2007 and her appointment is a significant step for the company as we gear up to begin our Phase 3 clinical trial. Dr. Carlson has been the key clinical and regulatory expert for Evoke through the entire development of EVK-001, including the most recent successful Phase 2b trial in gastroparesis. She has also participated in all of Evoke's meetings with the U.S. Food & Drug Administration (FDA). Dr. Carlson brings an enormous amount of talent and knowledge to Evoke and will be instrumental in the process we have ahead of us to reach FDA approval for EVK-001. Her track record in development of regulatory strategies and submissions and proven ability to drive clinical development will be invaluable to our efforts." Dr. Carlson has more than 22 years of experience in the development and post-marketing support of drugs, biologics, devices and diagnostics. She is one of the founders of Agility Clinical, Inc., a contract research organization dedicated to working with biotechnology companies and companies focused on orphan drug development, and is the founder of entreMeDica, a consulting company that provides chief medical officer services to biotechnology and life sciences companies. Dr. Carlson has held senior medical, regulatory, and/or clinical positions at Synteract, Inc., Prometheus Laboratories, Inc., XOMA (US) LLC, and Procter & Gamble and has participated in more than 50 clinical studies in various capacities. She holds a Bachelor's degree from Hunter College of the City University of New York, a D.M.D. from the Harvard School of Dental Medicine and an M.D. from Case Western Reserve University School of Medicine, and completed an internal medicine residency at The Cleveland Clinic Foundation.

Basic Compensation

Total Annual Compensation, USD 356,820
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 16,223
Fiscal Year Total, USD 373,043

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --